Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

November 2016 • Volume 15 • Number 11

Highlights of This Issue 2551

SMALL MOLECULE THERAPEUTICS

2553 **Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma**
Alok R. Singh, Shweta Joshi, Adam M. Burgoyne, Jason K. Sicklick, Sadakatsu Ikeda, Yuko Kono, Joseph R. Garlich, Guillermo A. Morales, and Donald L. Durden

2563 **AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies**
Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L. Dale, Scott Boiko, Tony Cheung, Jingwen Zhang, Shenghua Wen, Lillian Castriotta, Deborah Lawson, Michael Collins, Larry Bao, Miika J. Ahdesmaki, Graeme Walker, Greg O'Connor, Tammie C. Yeh, Alfred A. Rabow, Jonathan R. Dry, Corinne Reimer, Paul Lyne, Gordon B. Mills, Stephen E. Fawell, Michael J. Waring, Michael Zinda, Edwin Clark, and Huawei Chen

2575 **Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept**
Caroline Peyrode, Valérie Weber, Aurélien Voissière, Aurélie Maisonial-Besset, Aurélien Vidal, Philippe Auzeloux, Vincent Gaumet, Michèle Borel, Marie-Mélanie Dauplat, Mercedes Quintana, Françoise Degoul, Françoise Rédini, Jean-Michel Chezal, and Elisabeth Miot-Noirault

2586 **AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients**
Xiao Xu, Long Mao, Wanhong Xu, Wei Tang, Xiaoying Zhang, Biao Xi, Rongda Xu, Xin Fang, Jia Liu, Ce Fang, Li Zhao, Xiaobo Wang, Ji Jiang, Pei Hu, Hongyun Zhao, and Li Zhang

2598 **Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer**
Katarzyna A. Ludwik, J. Preston Campbell, Mingzong Li, Yu Li, Zachary M. Sandusky, Lejla Pasic, Miranda E. Sowder, David R. Brenin, Jennifer A. Pietenpol, George A. O'Doherty, and Deborah A. Lannigan

2609 **Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy**
Xiaojuan Wu, Yang Cao, Hui Xiao, Chenglong Li, and Jiayuh Lin

2620 **A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition**
Eun Hye Kim, Hyejin Jang, and Jong-Lyel Roh

2630 **E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models**
Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima, Masaki Mikamoto, Takayuki Nakagawa, Hiroko Kuramochi, Setsuo Funasaka, Satoshi Nagao, Naoko Hata Sugi, Kiyoshi Okamoto, Yukinori Minoshima, Yusuke Nakatani, Yuki Karoji, Isao Ohashi, Yoshinobu Yamane, Toshimi Okada, Tomohiro Matsushima, Junji Matsui, Masao Iwata, Toshimitsu Uenaka, and Akihiko Tsuruoka

2640 **Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma**
Ilaria Buondonno, Elena Gazzano, Sae Rin Jean, Valentina Audrito, Joanna Kopecka, Marilù Fanelli, Iris C. Salaroglio, Costanzo Costamagna, Ilaria Roato, Eleonora Mungo, Claudia M. Hattinger, Silvia Deaglio, Shana O. Kelley, Massimo Serra, and Chiara Riganti

2653 **Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts**
Nancy E. Chen, N. Vanessa Maldonado, Vazgen Khankaldyyan, Hiroyuki Shimada, Michael M. Song, Barry J. Maurer, and C. Patrick Reynolds

2665 **Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs**
Nancy Berte, Andrea Piée-Staffa, Nadine Piecha, Mengwan Wang, Kerstin Borgmann, Bernd Kaina, and Teodora Nikolova

Table of Contents

LARGE MOLECULE THERAPEUTICS

2679 **The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer**
Michael Mattie, Arthur Raitano, Kendall Morrison, Karen Morrison, Zili An, Linnette Capo, Alla Verlinsky, Monica Leavitt, Jimmy Ou, Rossana Nadell, Hector Aviña, Claudia Guevara, Faisal Malik, Ruth Moser, Steven Duniho, Jeffrey Coleman, Ying Li, Daniel S. Pereira, Fernando Doñate, Ingrid B.J. Joseph, Pia Challita-Eid, Dennis Benjamin, and David R. Stover

2688 **Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63**
Bart E.C.G. de Goeij, Tom Vink, Hendrik ten Napel, Esther C.W. Breij, David Satijn, Richard Wubbolts, David Miao, and Paul W.H.I. Parren

2698 **RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models**
Pavel Strop, Thomas-Toan Tran, Magdalena Dorywalska, Kathy Delaria, Russell Dushin, Oi Kwan Wong, Wei-Hsien Ho, Dahui Zhou, Aidong Wu, Eugenia Kraynov, Laura Aschenbrenner, Bora Han, Christopher J. O'Donnell, Jaume Pons, Arvind Rajpal, Dave L. Shelton, and Shu-Hui Liu

2709 **ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies**
Michael J. Flynn, Francesca Zammarchi, Peter C. Tyrer, Ayse U. Akarca, Narinder Janghra, Charles E. Britten, Carin E.G. Havenith, Jean-Noel Levy, Arnaud Tiberghien, Luke A. Masterson, Conor Barry, Francois D'Hooge, Teresa Marafioti, Paul W.H.I. Parren, David G. Williams, Philip W. Howard, Patrick H. van Berkel, and John A. Hartley

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2722 **Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models**
Derek P. Logsdon, Michelle Grimard, Meihua Luo, Safi Shahda, Yanlin Jiang, Yan Tong, Zhangsheng Yu, Nicholas Zyromski, Ernestina Schipani, Fabrizio Carta, Claudiu T. Supuran, Murray Korc, Mircea Ivan, Mark R. Kelley, and Melissa L. Fishel

2733 **IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal**
Christian B. Gocke, Ross McMillan, Qiuju Wang, Asma Begum, Vesselin R. Penchev, Syed A. Ali, Ivan Borrello, Carol Ann Huff, and William Matsui

2740 **The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells**
Raphaël Bergès, Aurélie Tchoghandjian, Stéphane Honoré, Marie-Anne Estève, Dominique Figarella-Branger, Felix Bachmann, Heidi A. Lane, and Diane Braguer

2750 **ERBB2 Overexpression Establishes ERBB3-Dependent Hypersensitivity of Breast Cancer Cells to Withaferin A**
Wenjun Liu, Annalise R. Barnette, Samita Andreansky, and Ralf Landgraf

2758 **Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2**
Alexey V. Danilov, Shanhu Hu, Bernardo Orr, Kristina Godek, Lisa Maria Mustachio, David Sekula, Xi Liu, Masanori Kawakami, Faye M. Johnson, Duane A. Compton, Sarah J. Freemantle, and Ethan Dmitrovsky

2767 **TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea**
Hannah R. Wardill, Joanne M. Bowen, Ysabella Z.A. Van Sebille, Kate R. Secombe, Janet K. Coller, Imogen A. Ball, Richard M. Logan, and Rachel J Gibson

2780 **c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer**
Raúl Rincón, Sandra Zazo, Cristina Chamizo, Rebeca Manso, Paula González-Alonso, Ester Martín-Aparicio, Ion Cristóbal, Carmen Cañadas, Rosario Perona, Ana Lluch, Pilar Eroles, Jesús García-Foncillas, Joan Albanell, Ana Rovira, Juan Madoz-Gúrpide, and Federico Rojo

2791 **Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells**
Sivalokanathan Sarveswaran, Ritisha Ghosh, Rujul Parikh, and Jagadananda Ghosh

Table of Contents

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

2802 **Identification of Pharmacodynamic Transcript Biomarkers in Response to *FGFR* Inhibition by AZD4547**
Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret Veldman-Jones, Joanne Wilson, Barry R. Davies, Jonathan R. Dry, Elaine Kilgour, and Paul D. Smith

2814 **Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection**
Stefan Stremitzer, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Satoshi Matsusaka, Anish Parekh, Satoshi Okazaki, Diana Hanna, Stephanie H. Astrow, Miriana Moran, Jose Hernandez, Craig Stephens, Stefan J. Scherer, Judith Stift, Friedrich Wrba, Thomas Gruenberger, and Heinz-Josef Lenz

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover features a molecular modeling diagram depicting molecular interaction between LY294002, the active moiety of SF1126, and the BRD4 bromodomain binding domain 1 (BD1). SF1126 is the first known dual inhibitor of PI3K and BRD4 in a single chemotype. The figure shows LY294002 and JQ1 docked at the key acetyl-lysine recognition pocket of BRD4-BD1. LY294002 is displayed with brown carbons and JQ1 with magenta carbons. SF1126 will enter clinical trials in liver cancer this year. For details, see the article by Singh, Joshi, and Burgoyne et al on page 2553.



Molecular Cancer Therapeutics

15 (11)

Mol Cancer Ther 2016;15:2551-2821.